Accessibility Menu
Cybin Stock Quote

Cybin (NYSEMKT: CYBN)

$5.81
(-4.0%)
-0.24
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$5.81
Daily Change
(-4.0%) $0.24
Day's Range
$5.71 - $6.12
Previous Close
$5.81
Open
$6.06
Beta
1.03
Volume
546,615
Average Volume
569,510
Market Cap
137.1M
Market Cap / Employee
$5.81M
52wk Range
$4.81 - $13.88
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$4.59
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Cybin Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CYBN-48.9%-70.66%-20.29%-77%
S&P+14.5%+93.32%+14.09%+88%

Cybin Company Info

Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.04M62.3%
Market Cap$176.49M-14.3%
Market Cap / Employee$3.53M0.0%
Employees500.0%
Net Income-$24.61M-127.2%
EBITDA-$24.59M-66.7%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$118.69M-11.4%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$44.50M0.0%
Short Term Debt$0.00M-100.0%

Ratios

Q2 2025YOY Change
Return On Assets-45.55%2.1%
Return On Invested Capital-65.42%-4.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$29.78M-49.7%
Operating Free Cash Flow-$29.55M-48.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.850.930.761.1015.23%
Price to Tangible Book Value1.211.391.181.8035.23%
Return on Equity-80.9%-58.8%-42.9%-53.6%8.64%
Total Debt$0.10M$0.00M$0.00M$44.50M28622.44%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.